N@N

Abiomed to Host PROTECT II Investor Meeting at ACC 2011

^{Published on 2011-03-24 05:40:54 - Market Wire}
 

DANVERS, Mass.--([ BUSINESS WIRE ])--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, will host a PROTECT II investor and analyst meeting and webcast from ACC 2011 on Monday, April 4, from 8:00 a" 9:00 a.m. ET.

The presentation will include the PROTECT II data, which will be presented by William Oa™Neill, M.D., University of Miami, the principal investigator for the PROTECT II trial. The meeting will also include comments from John Lasala, M.D., Barnes-Jewish Hospital, Karim Benali, M.D., Chief Medical Officer, Abiomed and Michael R. Minogue, Chairman, President, Chief Executive Officer, Abiomed.

The PROTECT II presentation will include patients enrolled and included in the interim analysis as well as those enrolled following the initiation of the interim analysis. There are 125 additional patients that were not included in the interim analysis.

Members of the investment community who are attending ACC 2011 in New Orleans are invited to attend this meeting. To register to attend the event, please contact Aimee Maillett at (978) 646-1553 or [ amaillett@abiomed.com ].

For those who are not attending the conference and would like to listen to the call live, please tune into the webcast via [ http://investor.abiomed.com ] or dial 866.804.6920; the international number is 857.350.1666. The access participant code is 62060523. A replay of this conference call will be available beginning at 11 a.m. ET on April 4, 2011 through 11:59 p.m. ET on April 18, 2011. The replay phone number is 888.286.8010; the international number is 617.801.6888. The replay access code is 95162601.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and the most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.